Xylem (XYL) Lifted to Hold at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Xylem (NYSE:XYL) from a sell rating to a hold rating in a research report report published on Saturday morning, Zacks.com reports.

According to Zacks, “Xylem believes that solid sales in utilities, industrial and commercial end-markets will benefit its top-line performance in the quarters ahead. This along with pricing and productivity initiatives will continue to boost profitability. For 2019, the company anticipates adjusted earnings of $3.20-$3.40 per share, up 11-18% year over year at the mid-point. Revenues are projected to increase 2-4% year over year to $5.3-$5.4 billion, with organic sales increasing 4-6% on the back of strengthening end-markets. However, material price inflation on account of tariffs might dent bottom-line performance. Also, foreign exchange headwind also remains a cause of concern, with 5 cents per share of headwinds expected in 2018. Year to date, the company's shares have underperformed the industry and also look relatively overvalued.”

Several other equities analysts have also issued reports on XYL. Boenning Scattergood reissued a buy rating on shares of Xylem in a report on Friday, March 22nd. Janney Montgomery Scott lowered shares of Xylem from a buy rating to a neutral rating in a report on Friday, March 29th. Oppenheimer set a $80.00 price target on shares of Xylem and gave the company a buy rating in a report on Monday, February 4th. ValuEngine lowered shares of Xylem from a buy rating to a hold rating in a report on Monday, February 4th. Finally, BMO Capital Markets reissued a buy rating and issued a $85.00 price target on shares of Xylem in a report on Monday, February 25th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nine have issued a buy rating to the stock. The company has an average rating of Buy and an average price target of $78.36.

Shares of XYL stock opened at $81.87 on Friday. Xylem has a 12-month low of $60.65 and a 12-month high of $82.64. The firm has a market capitalization of $14.66 billion, a PE ratio of 28.43, a PEG ratio of 1.39 and a beta of 1.14. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.51 and a quick ratio of 1.08.

Xylem (NYSE:XYL) last announced its quarterly earnings results on Thursday, January 31st. The industrial products company reported $0.88 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.88. Xylem had a net margin of 10.54% and a return on equity of 19.89%. The company had revenue of $1.39 billion during the quarter, compared to analyst estimates of $1.36 billion. Equities analysts expect that Xylem will post 3.32 EPS for the current fiscal year.

In related news, insider Tomas Brannemo sold 559 shares of the business’s stock in a transaction on Thursday, February 21st. The shares were sold at an average price of $74.44, for a total value of $41,611.96. Following the sale, the insider now directly owns 10,568 shares of the company’s stock, valued at approximately $786,681.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Kenneth Napolitano sold 35,526 shares of the business’s stock in a transaction on Monday, February 4th. The shares were sold at an average price of $70.17, for a total transaction of $2,492,859.42. The disclosure for this sale can be found here. Insiders sold a total of 80,195 shares of company stock worth $6,000,933 over the last ninety days. 0.81% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Thrivent Financial for Lutherans lifted its position in Xylem by 1.8% during the 4th quarter. Thrivent Financial for Lutherans now owns 7,864 shares of the industrial products company’s stock worth $525,000 after buying an additional 138 shares in the last quarter. Cascade Investment Advisors Inc. lifted its position in Xylem by 25.0% during the 4th quarter. Cascade Investment Advisors Inc. now owns 1,000 shares of the industrial products company’s stock worth $67,000 after buying an additional 200 shares in the last quarter. Independent Investors Inc. lifted its position in Xylem by 2.5% during the 4th quarter. Independent Investors Inc. now owns 9,500 shares of the industrial products company’s stock worth $633,000 after buying an additional 230 shares in the last quarter. Mercer Capital Advisers Inc. lifted its position in Xylem by 33.3% during the 4th quarter. Mercer Capital Advisers Inc. now owns 1,000 shares of the industrial products company’s stock worth $67,000 after buying an additional 250 shares in the last quarter. Finally, Macquarie Group Ltd. lifted its position in Xylem by 9.1% during the 4th quarter. Macquarie Group Ltd. now owns 3,104 shares of the industrial products company’s stock worth $207,000 after buying an additional 260 shares in the last quarter. 87.11% of the stock is currently owned by institutional investors and hedge funds.

About Xylem

Xylem Inc engages in the design, manufacture, and servicing of engineered products and solutions for the water and wastewater applications. It operates in three segments: Water Infrastructure, Applied Water, and Measurement & Control Solutions. The Water Infrastructure segment offers various products, including water and wastewater pumps; controls and systems; filtration, disinfection, and biological treatment equipment; and mobile dewatering equipment under the Flygt, Godwin, Wedeco, Sanitaire, and Leopold names for the transportation and treatment of water.

See Also: What is the balance sheet?

Get a free copy of the Zacks research report on Xylem (XYL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Xylem (NYSE:XYL)

Receive News & Ratings for Xylem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xylem and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Xylem  Lifted to Hold at Zacks Investment Research
Xylem Lifted to Hold at Zacks Investment Research
Trump says he won’t deliver tax returns to Congress
Trump says he won’t deliver tax returns to Congress
Pieris Pharmaceuticals  Upgraded to Buy at Zacks Investment Research
Pieris Pharmaceuticals Upgraded to Buy at Zacks Investment Research
Texas Capital Bancshares  Downgraded to Sell at Zacks Investment Research
Texas Capital Bancshares Downgraded to Sell at Zacks Investment Research
Analyzing Guardant Health  and Its Competitors
Analyzing Guardant Health and Its Competitors
Financial Contrast: Carbonite  and JMU Ltd-
Financial Contrast: Carbonite and JMU Ltd-


 
© 2006-2019 Zolmax.